TwinStrand Biosciences™, a spin-out of the University of Washington, is a novel genetic sequencing technology company leading the way in identifying rare genetic variants undetectable by current sequencing methods.
TwinStrand Biosciences develops and commercializes the Duplex Sequencing™ technology for DNA sequencing.
TwinStrand Biosciences was founded in 2015 and is headquartered in Seattle, Washington.
TwinStrand's highly-sensitive and highly-specific Duplex Sequencing™ technology delivers faster insights to researchers and clinicians in applications ranging from early cancer detection to genetic toxicology This data can inform critical decisions in clinical medicine, public health, and other fields of science – on a faster timescale, where actions are most impactful.
TwinStrand Biosciences is backed by Madrona Venture Group, Alexandria Venture Investments, Ridgeback Capital, Sahsen Ventures and others. The company raised $16M in Series A funding, including $12 million in new capital. This latest round brings TwinStrand's total funding to $27.9M to date.